|
|
???tair.name??? >
???browser.page.title.author???
|
"meyer t"???jsp.browse.items-by-author.description???
Showing items 11-25 of 25 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 臺大學術典藏 |
2021-05-13T03:03:46Z |
XThe proliferation-quiescence decision is controlled by a bifurcation in CDK2 activity at mitotic exit
|
Spencer S.L.; Cappell S.D.; FENG-CHIAO TSAI; Overton K.W.; Wang C.L.; Meyer T. |
| 臺大學術典藏 |
2021-05-13T03:03:46Z |
Brg1 governs distinct pathways to direct multiple aspects of mammalian neural crest cell development
|
Li W.; Xiong Y.; Shang C.; Twu K.Y.; Hang C.T.; Yang J.; Han P.; Lin C.-Y.; Lin C.-J.; FENG-CHIAO TSAI; Stankunas K.; Meyer T.; Bernstein D.; Pan M.; Chang C.-P. |
| 臺大學術典藏 |
2021-05-13T03:03:46Z |
A localized Wnt signal orients asymmetric stem cell division in vitro
|
Habib S.J.; Chen B.-C.; FENG-CHIAO TSAI; Anastassiadis K.; Meyer T.; Betzig E.; Nusse R. |
| 臺大學術典藏 |
2021-05-13T03:03:45Z |
Dosage of Dyrk1a shifts cells within a p21-Cyclin D1 signaling map to control the decision to enter the cell cycle
|
Chen J.-Y.; Lin J.-R.; FENG-CHIAO TSAI; Meyer T. |
| 臺大學術典藏 |
2021-05-13T03:03:45Z |
Dynamic recruitment of the curvature-sensitive protein ArhGAP44 to nanoscale membrane deformations limits exploratory filopodia initiation in neurons
|
Galic M.; FENG-CHIAO TSAI; Collins S.R.; Matis M.; Bandara S.; Meyer T. |
| 臺大學術典藏 |
2021-05-13T03:03:45Z |
Neuropilin-2 contributes to tumorigenicity in a mouse model of Hedgehog pathway medulloblastoma
|
Hayden Gephart M.G.; Su Y.S.; Bandara S.; FENG-CHIAO TSAI; Hong J.; Conley N.; Rayburn H.; Milenkovic L.; Meyer T.; Scott M.P. |
| 臺大學術典藏 |
2021-05-13T03:03:44Z |
Engulfed cadherin fingers are polarized junctional structures between collectively migrating endothelial cells
|
Hayer A.; Shao L.; Chung M.; Joubert L.-M.; Yang H.W.; FENG-CHIAO TSAI; Bisaria A.; Betzig E.; Meyer T. |
| 臺大學術典藏 |
2021-05-13T03:03:44Z |
A polarized Ca2+, diacylglycerol and STIM1 signalling system regulates directed cell migration
|
FENG-CHIAO TSAI; Seki A.; Yang H.W.; Hayer A.; Carrasco S.; Malmersj? S.; Meyer T. |
| 國立成功大學 |
2021 |
Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single-arm, phase 2 study
|
Harding, J.J.;Yang, T.-S.;Chen, Y.-Y.;Feng, Y.-H.;Yen, C.-J.;Ho, C.-L.;Huang, W.-T.;El, Dika I.;Akce, M.;Tan, B.;Cohen, S.A.;Meyer, T.;Sarker, D.;Lee, D.-W.;Ryoo, B.-Y.;Lim, H.Y.;Johnston, A.;Bomalaski, J.S.;O’Reilly, E.M.;Qin, S.;Abou-Alfa, G.K. |
| 國立成功大學 |
2019 |
First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma
|
Kim, R.D.;Sarker, D.;Meyer, T.;Yau, T.;Macarulla, T.;Park, J.-W.;Choo, S.P.;Hollebecque, A.;Sung, M.W.;Lim, H.-Y.;Mazzaferro, V.;Trojan, J.;Zhu, A.X.;Yoon, J.-H.;Sharma, Sharma S.;Lin, Z.-Z.;Chan, S.L.;Faivre, S.;Feun, L.G.;Yen, C.-J.;Dufour, J.-F.;Palmer, D.H.;Llovet, J.M.;Manoogian, Manoogian M.;Tugnait, M.;Stransky, N.;Hagel, M.;Kohl, N.E.;Lengauer, C.;Sherwin, C.A.;Schmidt-Kittler, O.;Hoeflich, K.P.;Shi, H.;Wolf, B.B.;Kang, Y.-K. |
| 國家衛生研究院 |
2018-04-05 |
ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma
|
Abou-Alfa, G;Qin, S;Ryoo, BY;Lu, SN;Yen, CJ;Feng, YH;Lim, HY;Izzo, F;Colombo, M;Sarker, D;Bolondi, L;Vaccaro, G;Harris, WP;Chen, Z;Hubner, RA;Meyer, T;Sun, W;Harding, JJ;Hollywood, EM;Ma, J;Wan, PJ;Ly, M;Bomalaski, J;Johnston, A;Lin, CC;Chao, Y;Chen, LT |
| 國立成功大學 |
2018 |
Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma
|
Abou-Alfa, G.K.;Qin, S.;Ryoo, B.-Y.;Lu, S.-N.;Yen, C.-J.;Feng, Y.-H.;Lim, H.Y.;Izzo, F.;Colombo, M.;Sarker, D.;Bolondi, L.;Vaccaro, G.;Harris, W.P.;Chen, Z.;Hubner, R.A.;Meyer, T.;Sun, W.;Harding, J.J.;Hollywood, E.M.;Ma, J.;Wan, P.J.;Ly, M.;Bomalaski, J.;Johnston, A.;Lin, C.-C.;Chao, Y.;Chen, L.-T. |
| 國家衛生研究院 |
2016-05 |
Phase III randomized study of second line ADI-peg 20 (A) plus best supportive care versus placebo (P) plus best supportive care in patients (pts) with advanced hepatocellular carcinoma (HCC)
|
Abou-Alfa, GK;Qin, SK;Ryoo, BY;Lu, SN;Yen, CJ;Feng, YH;Lim, HY;Izzo, F;Colombo, M;Sarker, D;Bolondi, L;Vaccaro, GM;Harris, WP;Chen, ZD;Hubner, R;Meyer, T;Bomalaski, JS;Lin, CC;Chao, Y;Chen, LT |
| 國立臺灣大學 |
2016 |
Safety and preliminary efficacy of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (aHCC): Interim analysis of the phase 1/2 CheckMate-040 study
|
Melero, I.; Sangro, B.; Yau, T.; Hsu, C.; Kudo, M.; Crocenzi, T.; Kim, T-Y.; Choo, S-P.; Trojan, J.; Meyer, T.; Welling, T. H., III; Yeo, W.; Chopra, A.; Anderson, J.; Dela Cruz, C.; Lang, L.; Neely, J.; El-Khoueiry, A.; 許駿 |
| 國立成功大學 |
2015-06-01 |
Combined analysis of two randomised Phase II trials comparing the efficacy and safety of nintedanib versus sorafenib in Caucasian and Asian patients with advanced hepatocellular carcinoma
|
Palmer, D.; Meyer, T.; Chao, Y.; Deptala, A.; Fartoux, L.; Feng, Y. -H.; Graham, J.; Lin, D. -Y.; Ma, Y. T.; Peck-Radosavljevic, M.; Ross, P.; Ryoo, B. -Y.; Yen, C. -J.; Hocke, J.; Vlassak, S.; Wenz, A.; Loembe, A. -B.; Cheng, A. -L. |
Showing items 11-25 of 25 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
